Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003110606 | SCV003782349 | uncertain significance | MEGF10-related myopathy | 2021-08-26 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine with leucine at codon 780 of the MEGF10 protein (p.Phe780Leu). The phenylalanine residue is highly conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant is present in population databases (rs371145876, ExAC 0.003%). This variant has not been reported in the literature in individuals affected with MEGF10-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004636698 | SCV005134017 | uncertain significance | Inborn genetic diseases | 2024-05-28 | criteria provided, single submitter | clinical testing | The c.2338T>C (p.F780L) alteration is located in exon 19 (coding exon 17) of the MEGF10 gene. This alteration results from a T to C substitution at nucleotide position 2338, causing the phenylalanine (F) at amino acid position 780 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |